Moderna and Merck Announce mRNA-4157 (V940), an Investigational Individualized Neoantigen Therapy, in …
mRNA-4157 (V940) in combination with KEYTRUDA reduced the risk of recurrence or death by 44% compared to KEYTRUDA alone in stage III/IV melanoma patients with high risk of recurrence following complete resection. Results from the Phase 2b KEYNOTE-942Â …
See Original Article
Accounting specialist Infusion merges with web and cloud shop NetValue – Reseller News
Merger will support development of Infusion Business Software's new SaaS accounting platform.
See Original Article
Spring brings green shoots of business optimism for Welsh accountants
A poll of accounting professionals found cautious optimism about the economic impact of the UK government's Spring Budget compared with the Autumn
See Original Article
Leave a Reply